Other Events ·
Enliven Therapeutics, Inc. stockholders approved an amendment to its Certificate of Incorporation to increase the…
ELVNEnliven Therapeutics, Inc.
Enliven Therapeutics, Inc. stockholders approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000 shares, effective June 9, 2026. The company also elected two Class III directors, Richard Fair and Lori Kunkel, M.D., and ratified the appointment of Deloitte & Touche LLP as its independent registered public accounting firm. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.